GeneDx Holdings
Closed (deSPAC)Health Care · rare disease genomic diagnostics
- What it is
- A private company in health care preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with CM Life Sciences, Inc. (CMLF) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
What the company says about itself
Web research — not auditedGeneDx provides genetic testing for rare disease diagnosis, offering services such as whole exome sequencing, whole genome sequencing, and trio testing. The company supports providers, patients, health systems, and biopharma partners through advanced genomic diagnostics and clinical interpretation.
- Markets:
- Genetic Testing | Rare Disease Diagnostics | Biopharma Research
- Products:
- Whole Exome Sequencing | Whole Genome Sequencing | Trio Testing | Targeted Variant Testing | Prenatal Genetic Testing | GeneDx Infinity
Source: https://www.genedx.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
GeneDx Holdings is merging with CM Life Sciences, Inc. (CMLF) currently marked Closed (deSPAC).
| Headline equity value | — |
How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is GeneDx Holdings going public?
GeneDx Holdings has an approved merger with the SPAC CM Life Sciences, Inc. (CMLF). Deal status: Closed (deSPAC).
Does GeneDx Holdings have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC